Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global burden of oesophageal and gastric cancer by histology and subsite in 2018
Melina Arnold, Jacques Ferlay, Mark I. van Berge Henegouwen, et al.
Gut (2020) Vol. 69, Iss. 9, pp. 1564-1571
Open Access | Times Cited: 433

Showing 1-25 of 433 citing articles:

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, et al.
The Lancet (2021) Vol. 398, Iss. 10294, pp. 27-40
Open Access | Times Cited: 1969
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly, Jaffer A. Ajani, Jarosław Kużdżał, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 13, pp. 1191-1203
Open Access | Times Cited: 1244
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Florian Lordick, Fátima Carneiro, Stefano Cascinu, et al.
Annals of Oncology (2022) Vol. 33, Iss. 10, pp. 1005-1020
Open Access | Times Cited: 759
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020
Eileen Morgan, Isabelle Soerjomataram, Harriet Rumgay, et al.
Gastroenterology (2022) Vol. 163, Iss. 3, pp. 649-658.e2
Open Access | Times Cited: 579
Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study
Harriet Rumgay, Kevin D. Shield, Hadrien Charvat, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 8, pp. 1071-1080
Open Access | Times Cited: 442
The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study
Eileen Morgan, Melina Arnold, M. Constanza Camargo, et al.
EClinicalMedicine (2022) Vol. 47, pp. 101404-101404
Open Access | Times Cited: 437
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Yuichiro� Doki, Jaffer A. Ajani, Ken Kato, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 5, pp. 449-462
Open Access | Times Cited: 420
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
Zhihao Lü, Junye Wang, Yongqian Shu, et al.
BMJ (2022), pp. e068714-e068714
Open Access | Times Cited: 279
Is early-onset cancer an emerging global epidemic? Current evidence and future implications
Tomotaka Ugai, Naoko Sasamoto, Hwa‐Young Lee, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 10, pp. 656-673
Open Access | Times Cited: 278
Alcohol and Cancer: Epidemiology and Biological Mechanisms
Harriet Rumgay, Neil Murphy, Pietro Ferrari, et al.
Nutrients (2021) Vol. 13, Iss. 9, pp. 3173-3173
Open Access | Times Cited: 222
Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries
Junjie Huang, Anastasios Koulaouzidis, Wojciech Marlicz, et al.
Cancers (2021) Vol. 13, Iss. 1, pp. 141-141
Open Access | Times Cited: 171
Revealing the transcriptional heterogeneity of organ‐specific metastasis in human gastric cancer using single‐cell RNA Sequencing
Haiping Jiang, Dingyi Yu, Penghui Yang, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 2
Open Access | Times Cited: 136
Current Status and Future Prospects for Esophageal Cancer
Mahdi Sheikh, Gholamreza Roshandel, Valerie McCormack, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 765-765
Open Access | Times Cited: 134
The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study
Ling Yang, Christiana Kartsonaki, Pang Yao, et al.
The Lancet Public Health (2021) Vol. 6, Iss. 12, pp. e888-e896
Open Access | Times Cited: 133
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
Manish A. Shah, Erin B. Kennedy, Ashley E. Alarcon-Rozas, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 7, pp. 1470-1491
Open Access | Times Cited: 116
Global variations in lung cancer incidence by histological subtype in 2020: a population-based study
Yanting Zhang, Salvatore Vaccarella, Eileen Morgan, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 11, pp. 1206-1218
Closed Access | Times Cited: 110
An updated profile of the cancer burden, patterns and trends in Latin America and the Caribbean
Marion Piñeros, Mathieu Laversanne, Enrique Barrios, et al.
The Lancet Regional Health - Americas (2022) Vol. 13, pp. 100294-100294
Open Access | Times Cited: 106
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial
Han Tang, Haiming Wang, Yong Fang, et al.
Annals of Oncology (2022) Vol. 34, Iss. 2, pp. 163-172
Open Access | Times Cited: 96
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
Jianming Xu, Yi Li, Qingxia Fan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 92
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
Yan Song, Bo Zhang, Dao Xin, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 473-482
Open Access | Times Cited: 92
METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability
Huafu Li, Chunming Wang, Linxiang Lan, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 3
Open Access | Times Cited: 78
The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis
Maryam Shirani, Reza Pakzad, Mohammad Hossein Haddadi, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 41
RE.GA.IN.: the Real-world Gastritis Initiative–updating the updates
Massimo Rugge, Robert M. Genta, Peter Malfertheiner, et al.
Gut (2024), pp. gutjnl-331164
Open Access | Times Cited: 36
Advances in diagnosis and management of cancer of the esophagus
Nathaniel Deboever, Christopher M. Jones, Kohei Yamashita, et al.
BMJ (2024), pp. e074962-e074962
Open Access | Times Cited: 35
Trends of gastric cancer burdens attributable to risk factors in China from 2000 to 2050
Feifan He, Shaoming Wang, Rongshou Zheng, et al.
The Lancet Regional Health - Western Pacific (2024) Vol. 44, pp. 101003-101003
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top